This 6-month study, with a 3-month follow up period, will compare the effectiveness of new
and traditional psychotherapies for depression with panic or anxiety symptoms.
Many depressed patients also experience significant symptoms of panic or anxiety. This study
will compare the effectiveness of a new therapy called interpersonal psychotherapy for
depression with panic or anxiety symptoms (IPT-PS) with that of traditional interpersonal
psychotherapy for depression (IPT).
Participants are randomly assigned to receive up to 24 weeks of treatment with either IPT-PS
or traditional IPT. Improvements in interpersonal functioning, quality of life, and
symptoms of depression and anxiety will be assessed at the end of therapy and at a 3-month
- DSM-IV diagnosis of major depression with co-existing panic or anxiety symptoms.
- History of manic episode(s). Patients who have had hypomanic episodes in the past
will be accepted into the study, provided they meet other admission criteria and are
not presenting in a current hypomanic or mixed episode.
- History of schizophrenia or schizoaffective disorder.
- Organic affective syndrome.
- Unspecified functional psychosis.
- Anorexia nervosa or bulimia nervosa. Patients meeting criteria for an eating disorder
not otherwise specified will not be excluded.
- Chronic drug or alcohol abuse/dependence within the past 2 years. Patients with abuse
related to episodes will not be excluded.
- DSM-IV criteria for borderline or antisocial personality disorder. Patients who meet
criteria for other Axis II disorders will not be excluded.
- Inpatient treatment due to suicide risk or psychotic symptoms.
- Index episode secondary to the effect of medically prescribed drugs.
- Significant or untreated medical illness, including cardiovascular disorder, renal or
liver disease, epilepsy, untreated hypertension, or unstabilized endocrine disease.
- Medical illness that would interfere with the best treatment strategy for the
- Current treatment with an antidepressant. Patients on a stable dose of anxiolytics
for at least 3 months prior to study participation who are able to maintain this
dosage throughout the study will not be excluded.
- Pregnant and breast-feeding women will be accepted into the study, but will not be
prescribed adjunctive medications.